|
Treatment Outcome
|
N05.715.360.575.575.800 |
|
|
Cytoreduction Surgical Procedures
|
D065426 |
[Operative procedures carried out to reduce a mass of tissue, for example, to reduce the total amount of tissue composing a tumor.
] |
|
Factor Xa Inhibitors
|
D065427 |
[Endogenous factors and drugs that inhibit or block the activity of FACTOR XA.
] |
|
Ribonucleoprotein, U2 Small Nuclear
|
D12.776.664.962.500.875.605 |
|
|
Xanthogranuloma, Juvenile
|
C15.604.250.410.900 |
|
|
Histiocytosis, Non-Langerhans-Cell
|
C15.604.250.410 |
|
|
Evidence-Based Pharmacy Practice
|
H02.249.937 |
|
|
Madagascar
|
Z01.639.520.500 |
|
|
Cestrum
|
B01.650.940.800.575.912.250.908.500.166 |
|
|
Ribonucleoprotein, U1 Small Nuclear
|
D12.776.664.962.500.875.600 |
|
|
Dilatation, Pathologic
|
C23.300.325 |
|
|
Quality Improvement
|
J01.293.754 |
|
|
Occupational Health Physicians
|
N02.360.810.675 |
|
|
Broadly Neutralizing Antibodies
|
D12.776.124.486.485.114.244.500 |
|
|
Antibodies, Neutralizing
|
D12.776.124.486.485.114.244 |
|
|
Cholesterol Ester Storage Disease
|
C16.320.565.595.201 |
|
|
Lysosomal Storage Diseases
|
C16.320.565.595 |
|
|
Osteosclerosis
|
C05.116.099.708.702 |
|
|
Osteochondrodysplasias
|
C05.116.099.708 |
|
|
Rh Isoimmunization
|
G12.122.780 |
|
